Bet v 1-specific B-cell receptor and immunoglobulin (Bet v 1-BCR/Ig)

Bet v 1-specific B-cell receptors (BCRs) and antibodies represent the primary immunological targets in the management of birch pollen allergy, the most common cause of spring pollinosis in temperate climates (UniProt P15494). The target complex involves the recognition of the major birch allergen, Bet v 1 (a PR-10 protein), by membrane-bound BCRs on B cells and secreted IgE/IgG antibodies (PubMed: 25210000). In allergic pathology, Bet v 1-specific IgE mediates the degranulation of mast cells and basophils upon allergen cross-linking, leading to symptoms of allergic rhinitis and asthma (PubMed: 24565705). Therapeutic strategies focus on modulating this B-cell response through allergen-specific immunotherapy (AIT), which induces a class switch toward protective IgG4 antibodies that compete with IgE for allergen binding (PubMed: 21464211). Additionally, high-affinity monoclonal antibodies, such as the REGN5713/5714 combination, are designed to neutralize Bet v 1 epitopes, effectively preventing the allergen from interacting with the BCR or IgE (ClinicalTrials.gov: NCT03918876). Understanding the BCR repertoire and epitope specificity is crucial for developing next-generation biologics and personalized vaccines for allergic rhinitis and associated pollen-food allergy syndromes.

Other names

Bet v 1-specific B-cell receptors and antibodies recognizing birch pollen epitopesBirch pollen-specific B-cell receptorBet v 1-specific IgEBet v 1-specific IgGMajor birch pollen allergen receptor

Allergen-specific immunotherapy (AIT) induces immune tolerance by shifting the B-cell response from IgE to IgG4 production and modulating T-cell activity (PubMed: 24565705). Monoclonal antibodies neutralize the Bet v 1 allergen, preventing it from cross-linking IgE on effector cells or binding to B-cell receptors (ClinicalTrials.gov: NCT03918876).